BioVie Past Earnings Performance
Past criteria checks 0/6
BioVie has been growing earnings at an average annual rate of 4.8%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
4.8%
Earnings growth rate
37.8%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | n/a |
Return on equity | -181.7% |
Net Margin | n/a |
Last Earnings Update | 30 Sep 2024 |
Revenue & Expenses Breakdown
How BioVie makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 0 | -27 | 9 | 16 |
30 Jun 24 | 0 | -33 | 9 | 23 |
31 Mar 24 | 0 | -37 | 9 | 29 |
31 Dec 23 | 0 | -43 | 9 | 35 |
30 Sep 23 | 0 | -51 | 11 | 35 |
30 Jun 23 | 0 | -50 | 12 | 33 |
31 Mar 23 | 0 | -49 | 12 | 31 |
31 Dec 22 | 0 | -41 | 12 | 23 |
30 Sep 22 | 0 | -31 | 9 | 21 |
30 Jun 22 | 0 | -26 | 10 | 17 |
31 Mar 22 | 0 | -150 | 7 | 143 |
31 Dec 21 | 0 | -145 | 7 | 140 |
30 Sep 21 | 0 | -143 | 7 | 136 |
30 Jun 21 | 0 | -184 | 5 | 133 |
31 Mar 21 | 0 | -71 | 5 | 2 |
31 Dec 20 | 0 | -69 | 3 | 2 |
30 Sep 20 | 0 | -59 | 1 | 1 |
30 Jun 20 | 0 | -34 | 1 | 1 |
31 Mar 20 | 0 | -15 | 1 | 1 |
31 Dec 19 | 0 | -16 | 1 | 1 |
30 Sep 19 | 0 | -23 | 1 | 1 |
30 Jun 19 | 0 | -2 | 1 | 1 |
31 Mar 19 | 0 | -2 | 1 | 1 |
31 Dec 18 | 0 | -2 | 1 | 1 |
30 Sep 18 | 0 | -2 | 1 | 1 |
30 Jun 18 | 0 | -2 | 2 | 0 |
31 Mar 18 | 0 | -2 | 2 | 0 |
31 Dec 17 | 0 | -2 | 1 | 0 |
30 Sep 17 | 0 | -2 | 1 | 0 |
30 Jun 17 | 0 | -1 | 1 | 0 |
31 Mar 17 | 0 | -1 | 1 | 0 |
31 Dec 16 | 0 | -1 | 1 | 0 |
30 Sep 16 | 0 | -1 | 0 | 0 |
30 Jun 16 | 0 | 0 | 0 | 0 |
31 Mar 16 | 0 | 0 | 0 | 0 |
31 Dec 15 | 0 | 0 | 0 | 0 |
30 Sep 15 | 0 | 0 | 0 | 0 |
30 Jun 15 | 0 | 0 | 0 | 0 |
31 Mar 15 | 0 | 0 | 0 | 0 |
31 Dec 14 | 0 | 0 | 0 | 0 |
30 Sep 14 | 0 | 0 | 0 | 0 |
Quality Earnings: BIVI is currently unprofitable.
Growing Profit Margin: BIVI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BIVI is unprofitable, but has reduced losses over the past 5 years at a rate of 4.8% per year.
Accelerating Growth: Unable to compare BIVI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BIVI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: BIVI has a negative Return on Equity (-181.72%), as it is currently unprofitable.